SLC-0111

DRUG2 trials

Sponsors

Welichem Biotech Inc., British Columbia Cancer Agency

Conditions

Metastatic Pancreatic Ductal AdenocarcinomaSolid Tumours

Phase 1

Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours

CompletedNCT02215850

Welichem Biotech Inc.Solid Tumours

Start: 2014-10-31End: 2016-03-31Updated: 2016-05-17

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

TerminatedNCT03450018

British Columbia Cancer AgencyMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2019-01-10End: 2024-05-16Updated: 2024-05-24

Related Papers

Abstract CT161: Phase I clinical trials of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors

Cancer Research2020-08-15

Structure activity study of carbonic anhydrase IX: Selective inhibition with ureido-substituted benzenesulfonamides.

2017-03-1946 citations

Abstract B51: Regulation of HIF1α under hypoxia by APE1/Ref-1 impacts CA9 expression: Dual-targeting in patient-derived 3D pancreatic cancer models

Cancer Research2016-12-142 citations

Abstract 754: Targeting carbonic anhydrase IX in multiple pancreatic ductal adenocarcinoma models results in tumor growth inhibition and increased survival

Cancer Research2016-07-15